Interleukin 17 Receptor A Modulates Monocyte Subsets and Macrophage Generation In Vivo

Shuwang Ge¹,³, Barbara Hertel¹, Nathan Susnik¹, Song Rong¹, Anna M. Dittrich², Roland Schmitt¹, Hermann Haller¹, Sibylle von Vietinghoff¹,²

1 Department of Medicine, Hannover Medical School, Hannover, Germany, 2 Department of Pediatrics, Hannover Medical School, Hannover, Germany, 3 Department of Nephrology, Tongji Hospital, Huazhong University, Wuhan, China

Abstract

Interleukin (IL)-17A signaling via interleukin 17 receptor A (Il17ra) contributes to the inflammatory host response by inducing recruitment of innate immune cells, but also plays a role in homeostatic neutrophilic granulocyte regulation. Monocytes, the other main innate immune cell, have a longer life span and can pursue multiple differentiation pathways towards tissue macrophages. Monocytes are divided into two subpopulations by expression of the Ly6C/Gr1 surface marker in mice. We here investigated the role of Il17ra in monocyte homeostasis and macrophage generation. In Il17ra⁻/⁻ and in mixed bone marrow chimeric wt/Il17ra⁻/⁻ mice, the concentrations of circulating Il17ra⁻/⁻ Gr1low monocytes were significantly decreased compared to wt cells. Pulmonary, splenic and resident peritoneal Il17ra⁻/⁻ macrophages were significantly fewer than of wt origin. Bone marrow progenitor and monocyte numbers were equal, but the proportion of Il17ra⁻/⁻ Gr1low monocytes was already decreased at bone marrow level. After monocyte depletion, initial Gr1high and Gr1low monocyte regeneration of Il17ra⁻/⁻ and wt cells was very similar. However, Il17ra⁻/⁻ Gr1low counts were not sustained. After labeling with either fluorescent beads or BrdU, Il17ra⁻/⁻ Gr1high monocyte transition to Gr1low cells was not detectable unlike wt cells. Monocyte recruitment in acute peritonitis, which is known to be largely due to Gr1high cell migration, was unaffected in an identical environment. Unilateral ureteral obstruction induces a less acute inflammatory and fibrotic kidney injury. Compared to wt cells in the same environment, Il17ra⁻/⁻ macrophage accumulation in the kidney was decreased. In the absence of Il17ra on all myeloid cells, renal fibrosis was significantly attenuated. Our data show that Il17ra modulates Gr1low monocyte counts and suggest defective Gr1high to Gr1low monocyte transition as an underlying mechanism. Lack of Il17ra altered homeostatic tissue macrophage formation and diminished renal inflammation and fibrosis. Il17ra appears to be a novel modulator of monocyte phenotype and possible therapeutic target in renal fibrosis.

Introduction

Monocytes are innate immune cells that frequently mediate early immune response [1–3]. Life span is considerably longer than that of the other main innate myeloid cells, neutrophilic granulocytes, and monocytes can differentiate into macrophages with heterogeneous functions regarding cytokine production and antigen presentation in the target tissues. While some recruitment mechanisms of granulocytes and monocytes are similar, surface receptor expression [4] and mechanisms of mobilization from the bone marrow differ substantially [3].

Two CD115 (M-CSF-receptor)⁺ monocyte subpopulations can be distinguished in mice [1–3]. Surface molecules are differentially expressed, including the fractalkine receptor CX3CR1, the chemokine receptor CCR2, the GPI linked surface molecule Ly6C (also detected by the Gr1 antibody) and the integrin subunit CD11c [5,6]. The two main subpopulations are Gr1highCX3CR1⁻/⁻CD11c⁻ and Gr1highCX3CR1⁻/⁻CD11c⁺, sometimes termed “inflammatory” and Gr1lowCX3CR1⁻/⁻CD11c⁻ and Gr1lowCX3CR1⁻/⁻CD11c⁺, sometimes termed “resident” monocytes [1–3]. Pharmacological blockade of the M-CSF receptor preferentially depletes Gr1low monocytes [7,8]. Recently, a role for the nuclear receptor NUR77 in maintenance of monocyte counts, most markedly the Gr1low subtype, has been reported [9].

A number of observations suggest that most circulating Gr1low monocytes develop from Gr1high monocytes in the periphery [10–12]. While a mechanism driving this transition remains to be determined, the evidence includes that the proportion of Gr1high cells is higher in bone marrow than peripheral blood, that Gr1low cells reappear before Gr1low cells after monocyte depletion [10,11], and that Gr1high cells labeled with fluorescent latex beads [13] or BrdU [12] can transition to Gr1low monocytes.

Both monocyte subtypes contribute to tissue macrophages and myeloid antigen presenting cells. For generation of many macrophage types, especially in acute inflammation, Gr1high monocytes appear to be the predominant subtype [1–3]. However, adoptive transfer experiments have demonstrated that Gr1low monocytes give rise to splenic myeloid dendritic cells [14] and pulmonary macrophages [15] and very recently, with the use of novel genetic models, a significant contribution of...
Gr1<sup>low</sup>•CX3CR<sup>high</sup> monocytes to resident macrophage populations in many organs has been documented [12]. Macrophages in the atherosclerotic aorta develop from both subtypes [16]. In acute inflammation in listerial peritonitis, Neutrophil recruitment is enhanced by IL-17 e.g. in encephalitis, ischemia-reperfusion injury and solid allograft rejection [18,19]. However, evidence of a direct IL-17 effect on encephalitis, ischemia-reperfusion injury and solid allograft immunity. Neutrophil recruitment is enhanced by IL-17 e.g. in acute peritonitis were decreased in IL-17 and IL-17 receptor A deficient (Il17ra<sup>−/−</sup>) mice [21]. Monocytes differentially express Il17ra and macrophage cytokine secretion is influenced by IL-17A [23].

Here we investigated whether or not IL-17 signaling influences monocyte homeostasis, subpopulations and macrophage generation at rest and during inflammation in vivo. Our results indicate a significant impact of monocyte IL-17 receptor expression on monocyte counts and macrophage generation at an individual cell level.

Materials and Methods

Animals

Wild-type (wt, CD45.2) C57BL/6 and congenic B6.SJL-PtprcaPepcb/J (CD45.1) mice were from Jackson Labs (Bar Harbor, ME), mice lacking IL-17 receptor (Il17ra<sup>−/−</sup>) from Amgen (Thousand Oaks, CA) and genotyped by PCR. Il17ra<sup>−/−</sup> mice were >95% C57BL/6 background. Mice were kept in specific-pathogen-free conditions. Blood was collected via tail bleeds into EDTA-anti-coagulated whole blood.

Bone marrow transplantation

Lethal irradiations were performed in a <sup>137</sup>Cs irradiator (10 Gy), and mice were reconstituted with unfractioned bone marrow from wt (CD45.1) and Il17ra<sup>−/−</sup> (CD45.2) mice at a 1:1 ratio verified by flow cytometry into wt (CD45.2) mice. Mice were treated with trimethoprim-sulphomethoxazole in drinking water for two weeks after transplantation. Experiments were conducted 6-12 weeks after bone marrow transplantation.

Monocyte depletion by liposomal clodronate and labeling with latex microspheres

Liposomal clodronate was kindly provided by Dr. van Rooijen [24]. Mice were injected intravenously with 200 μl of clodronate or control PBS liposomes (5 mg/ml). This depleted monocytes both in peripheral blood and bone marrow (data not shown). FITC-labeled latex microspheres (0.5 μm, Polysciences, Eppelheim, Germany) were injected i.v. at a dose of 10 μl/mouse.

Thioglycollate-induced peritonitis and unilateral ureteral obstruction

For induction of peritonitis, 1 ml of 3% thioglycollate (Sigma-Aldrich, St. Louis, MO) was injected i.p., and cells were recovered after 10 h or 3 days by washing twice with 5 ml PBS. Unilateral ureteral obstruction surgery was performed and tissues analyzed on day 7 as described [25]. Anti-α-Smooth Muscle Actin-Alexa547 (1A4, Sigma, St. Louis, MO, USA). Images were obtained with a Zeiss Axioplan-2 microscope with 20× and 40× original magnification using AxioVision 4.6 (Zeiss, Jena, Germany). Quantification was conducted with NIH ImageJ. Values represent means of 3-6 high power fields/animal.

Cell preparation and staining for flow cytometry

Single cells suspensions from blood, bone marrow, spleen, kidney and lung were prepared. Lungs and kidneys was digested with a cocktail of 125 U/ml collagenase XI, 450 U/ml collagenase I, 60 U/ml DNase I, and 60 U/ml hyaluronidase (Sigma-Aldrich) as described [21]. For assessment of TNFα production, monocytes from mixed bone marrow chimeric mice were stimulated for 60 min with 1 μg/ml LPS (E.coli, Sigma) at 37°C in EDTA-anti-coagulated whole blood.

Figure 1. Decreased Gr1<sup>low</sup> monocyte counts in IL-17 receptor A deficient mice. (A,B) Peripheral blood total white cell (A) and monocyte (B) counts were assessed by an automated analyzer in wild type (wt) and Interleukin-17 receptor A-deficient (Il17ra<sup>−/−</sup>) mice (n = 9–12). (C–E) Gr1<sup>high</sup> and Gr1<sup>low</sup> monocyte subgroups were analyzed by flow cytometry after gating for CD11b<sup>+</sup>CD115<sup>+</sup> events (example in C, D: proportion of Gr1<sup>high</sup> monocytes and E: absolute concentrations in wt and Il17ra<sup>−/−</sup> mice, n = 9–12, t-tests).

doi:10.1371/journal.pone.0085461.g001
mRNA isolation and qPCR

Bone marrow CD11b^CD115^ monocytes were sorted (FACS-Aria) for Ly6C expression and mRNA was isolated using Nucleospin® RNA II Kit (Macherey-Nagel, Duren, Germany) and reversely transcribed with M-MLV-RT (Promega, Mannheim, Germany) according to the manufacturer’s instructions. Realtime PCR was performed on a LightCycler®480 using SybrGreen (Roche, Grenzach-Wyhlen, Germany). Primers were selected using PrimerBank as follows: Il17ra: fw: AGTGTCTCCCTTACCCAGCACG, rev: GAAACCAGCCAAGGTTACGACCC, Il17rb: fw: GCCGTGCTAAACCCAGCTGTAATG, rev: CCCGTGTAATGGAATCCTGTGF, Il17rc: fw: GCGTCCTGATGTGACAGTGT, rev: TGAGGCAGCATTACGTAAGAG, Il17re: fw: TCTGCGCAGTCACAGCGCTTCA, rev: GGTCTGGGAGGGGTGAGTG, collagen I: fw: TGT CCC AAC CCC CAA AGA C, rev: CCA CCG ACT CCT ACA TCT TCT GA, CTGF: fw: AAG ACC TGT GGA ATG GGC, rev: TGG TGC AGC CAG AAA GCT C, fibronectin: fw: GCC CAG GGG AAG AAA AGG AG, rev: TTT AGT CAG GGA TGG GAG GAG AG, HPRT: fw: CAGTCGCAAGGTTCTGATGGTGACAATGT, rev: TGGACGCAGGTACTG. Products were confirmed by melting curve analysis. mRNA levels of Il17ra, Il17rb, Il17rc, and Il17re were analyzed from bone-marrow and expression of IL-17 receptor subunits analyzed by qPCR (means of n = 2 independent cell sorts).

Results

Gr1<sub>low</sub> monocyte deficiency in the absence of IL-17 receptor A

To test for a role of IL-17 receptor A in monocyte homeostasis, we analyzed peripheral blood monocytes in wildtype (wt) and Il17ra<sup>−/−</sup> mice. Total white blood counts and the concentration of monocytes were very similar (figure 1A, B), but the proportion of Gr1<sub>high</sub> monocytes was significantly elevated in Il17ra<sup>−/−</sup> mice (figure 1C, D). This was not caused by an increase in Gr1<sub>high</sub>, but a decrease in Gr1<sub>low</sub> absolute monocyte counts (figure 1E).

To dissect between systemic effects of IL-17 receptor deficiency and cell intrinsic effects in Il17ra<sup>−/−</sup> monocytes, mixed chimeric mice were generated by reconstitution of CD45.2 wt mice with a 1:1 mixture of wt (CD45.1) and Il17ra<sup>−/−</sup> (CD45.2) bone marrow. We first investigated possible contamination with host (CD45.2) monocytes, mixed chimeric mice were analyzed using paired t-test or repeated measures ANOVA if more than two measures were compared. Data are expressed as mean±SEM. P-values <0.05 were considered significant and are indicated in the figures as *p<0.05, **p<0.01, and ***p<0.001.

The following antibodies were used: Anti-mouse lineage cocktail (BD Biosciences), CD3 (17A2), CD11b (M1/70), CD11c (N418), CD19 (6D5), CD34 (RAM34), CD45 (30-F11), CD45.1 (A20), CD45.2 (104), CD103 (2E7), CD115 (AFS98), CD117 (2B8), Gr1 (RB6-8C5), F4/80 (BM8), IL-17ra (PA-J-17R), Ly6C (HK1.4), Sca-1 (D7), TNFα (MP6-XT22). Antibodies were purchased from BD Biosciences (Heidelberg, Germany), BioLegend (San Diego, CA), eBioscience (San Diego, CA), or Invitrogen (Carlsbad, CA). Near infrared LIVE/DEAD® Fixable Dead Cell Stain Kit (Invitrogen, Carlsbad, CA), BD-Fix-Perm and BrdU flow kit (BD Pharmingen, San Jose, CA) were used according to the manufacturer’s instructions. Flow cytometry analysis was performed on a BD Biosciences FACSCanto or LSRII, cells were sorted using a FACSAria. Data were analyzed using FlowJo software (Tree Star, Ashland, OR). Monocytes were defined as CD115<sup>+</sup> leukocytes and subdivided by genotype with use of CD45.1 and CD45.2 markers before analysis of their phenotype (Gr1, Ly6C etc.) was performed.

The following antibodies were used: Anti-mouse lineage cocktail (BD Biosciences), CD3 (17A2), CD11b (M1/70), CD11c (N418), CD19 (6D5), CD34 (RAM34), CD45 (30-F11), CD45.1 (A20), CD45.2 (104), CD103 (2E7), CD115 (AFS98), CD117 (2B8), Gr1 (RB6-8C5), F4/80 (BM8), IL-17ra (PA-J-17R), Ly6C (HK1.4), Sca-1 (D7), TNFα (MP6-XT22). Antibodies were purchased from BD Biosciences (Heidelberg, Germany), BioLegend (San Diego, CA), eBioscience (San Diego, CA), or Invitrogen (Carlsbad, CA). Near infrared LIVE/DEAD® Fixable Dead Cell Stain Kit (Invitrogen, Carlsbad, CA), BD-Fix-Perm and BrdU flow kit (BD Pharmingen, San Jose, CA) were used according to the manufacturer’s instructions. Flow cytometry analysis was performed on a BD Biosciences FACSCanto or LSRII, cells were sorted using a FACSAria. Data were analyzed using FlowJo software (Tree Star, Ashland, OR). Monocytes were defined as CD115<sup>+</sup> leukocytes and subdivided by genotype with use of CD45.1 and CD45.2 markers before analysis of their phenotype (Gr1, Ly6C etc.) was performed.

The following antibodies were used: Anti-mouse lineage cocktail (BD Biosciences), CD3 (17A2), CD11b (M1/70), CD11c (N418), CD19 (6D5), CD34 (RAM34), CD45 (30-F11), CD45.1 (A20), CD45.2 (104), CD103 (2E7), CD115 (AFS98), CD117 (2B8), Gr1 (RB6-8C5), F4/80 (BM8), IL-17ra (PA-J-17R), Ly6C (HK1.4), Sca-1 (D7), TNFα (MP6-XT22). Antibodies were purchased from BD Biosciences (Heidelberg, Germany), BioLegend (San Diego, CA), eBioscience (San Diego, CA), or Invitrogen (Carlsbad, CA). Near infrared LIVE/DEAD® Fixable Dead Cell Stain Kit (Invitrogen, Carlsbad, CA), BD-Fix-Perm and BrdU flow kit (BD Pharmingen, San Jose, CA) were used according to the manufacturer’s instructions. Flow cytometry analysis was performed on a BD Biosciences FACSCanto or LSRII, cells were sorted using a FACSAria. Data were analyzed using FlowJo software (Tree Star, Ashland, OR). Monocytes were defined as CD115<sup>+</sup> leukocytes and subdivided by genotype with use of CD45.1 and CD45.2 markers before analysis of their phenotype (Gr1, Ly6C etc.) was performed.

The following antibodies were used: Anti-mouse lineage cocktail (BD Biosciences), CD3 (17A2), CD11b (M1/70), CD11c (N418), CD19 (6D5), CD34 (RAM34), CD45 (30-F11), CD45.1 (A20), CD45.2 (104), CD103 (2E7), CD115 (AFS98), CD117 (2B8), Gr1 (RB6-8C5), F4/80 (BM8), IL-17ra (PA-J-17R), Ly6C (HK1.4), Sca-1 (D7), TNFα (MP6-XT22). Antibodies were purchased from BD Biosciences (Heidelberg, Germany), BioLegend (San Diego, CA), eBioscience (San Diego, CA), or Invitrogen (Carlsbad, CA). Near infrared LIVE/DEAD® Fixable Dead Cell Stain Kit (Invitrogen, Carlsbad, CA), BD-Fix-Perm and BrdU flow kit (BD Pharmingen, San Jose, CA) were used according to the manufacturer’s instructions. Flow cytometry analysis was performed on a BD Biosciences FACSCanto or LSRII, cells were sorted using a FACSAria. Data were analyzed using FlowJo software (Tree Star, Ashland, OR). Monocytes were defined as CD115<sup>+</sup> leukocytes and subdivided by genotype with use of CD45.1 and CD45.2 markers before analysis of their phenotype (Gr1, Ly6C etc.) was performed.
lymphocytes and granulocytes, but significantly decreased among monocytes (figure 3A). Consistently, peripheral blood concentrations of Il17ra-/- monocytes were significantly lower than wt monocytes (figure 3B). The proportion of Gr1<sup>high</sup> monocytes was significantly higher among Il17ra-/- than wt cells (figure 3C). Principally the same results were found using the Ly6C antibody (figure 3D). This was reflected by a much more marked decrease in absolute Il17ra-/-Gr1<sup>low</sup> monocyte blood concentrations compared to wt cells in identical environments (figure 3E). There was no significant difference in the proportion of dead monocytes of either genotype or subtype in the circulation (figure 3F), only a non-significant tendency towards even less cell death in Il17ra-/- Gr1<sup>low</sup> monocytes.

These data suggest a deficiency in monocytes, most markedly Gr1<sup>low</sup> cells, in the absence of IL-17 signal. The fact that this was even more marked in an identical environment suggests a role of the IL-17 signal on a cellular level.

**IL-17ra<sup>-/-</sup> monocyte derived macrophage generation under homeostatic conditions**

As there was no indication of enhanced cell death in Il17ra<sup>-/-</sup>Gr1<sup>low</sup> monocytes, we next tested whether or not their deficiency in blood was due to increased migration into tissues. Gr1<sup>low</sup> monocytes are known precursors of pulmonary tissue macrophages [15]. Flow cytometric analysis of lungs of mixed chimeric wt/Il17ra<sup>-/-</sup> mice revealed that Il17ra<sup>-/-</sup> cells were underrepresented in pulmonary CD115<sup>+</sup> monocytes and both CD11b<sup>+</sup>F4/80<sup>+</sup> and CD11b<sup>+</sup>CD11c<sup>+</sup> macrophages (figure 4A,B). This does not suggest an increased migration of the gene deficient cells into the tissue. The results for the CD11b<sup>+</sup> myeloid compartment were significantly different from the findings in CD103<sup>+</sup>CD11b<sup>-</sup> non-myeloid dendritic cells. Here, no decrease in CD45.2 cells was noted (figure 4A,B). Indeed, there was a relative increase over CD45.1, which might be an Il17ra<sup>-/-</sup> phenotype but would also be expected in any cell type not completely replaced after lethal irradiation due to residual recipient cells.

Macrophages were also assessed in the spleen and resting peritoneal cavity. Also in these compartments, the proportion of Il17ra<sup>-/-</sup> among all CD11b<sup>+</sup> cells and among macrophages in mixed bone marrow chimeric wt/Il17ra<sup>-/-</sup> mice was significantly lower than the expected 50% (figure 4C,D).

These data suggest the IL-17 signal at the level of the individual cell to be involved in tissue myeloid macrophage homeostasis in the absence of inflammation.
Bone marrow Gr1<sub>low</sub> monocyte formation

We next tested whether the observed monocyte defect was due to a defect in monocyte generation in the bone marrow. To this end, bone marrow myeloid cell maturation and monocytes were further investigated in wt/Il17ra<sup>-/-</sup> mixed chimeras to provide identical environments for development (figure 5). Bone marrow progenitors, defined as described [28], were very similar for the genotypes (figure 5A,B). Similarly, the proportion of Il17ra<sup>-/-</sup>CD11b<sup>+</sup>CD115<sup>+</sup> monocytes in the bone marrow did not differ from the expected 50% (figure 5C). However a small, but very consistent and significant increase in the proportion of Il17ra<sup>-/-</sup>Gr1<sup>high</sup> cells was observed (figure 5D).

These data show that the decrease in the proportion of Gr1<sub>low</sub>Il17ra<sup>-/-</sup> monocytes commences at the bone marrow level.

Peripheral Gr1<sub>low</sub> monocyte recovery

Given the unchanged total monocyte population in the bone marrow, we investigated monocyte repopulation after depletion with liposomal clodronate in mixed chimeric wt/Il17ra<sup>-/-</sup> mice [24]. As described, clodronate completely abolished peripheral blood monocyte counts on day one after application (data not shown). During initial recovery on day three, the proportion of Il17ra<sup>-/-</sup>Gr1<sup>high</sup> cells was equal to wt cells (figure 6A), as was the proportion of Gr1<sup>high</sup> cells in both genotypes (figure 6B) which is reflected in similar absolute counts of the monocyte subtypes of either genotype at this timepoint (figures 6C,D). This suggests no major deficiency in initial monocyte recovery. However, during the following days, which brought normalization of wt absolute monocyte counts of each subgroup and the proportion of Gr1<sup>high</sup> cells ([10], figure 6), Il17ra<sup>-/-</sup> cell counts decreased, largely due to a stop in the rise of absolute numbers of Gr1<sub>low</sub> cells (figure 6D).

These data suggest no defect in initial generation of Gr1<sub>low</sub> monocytes, but rather in maintenance of their numbers as the reason for low Il17ra<sup>-/-</sup> monocyte counts.

Monocyte Gr1<sub>high</sub> to Gr1<sub>low</sub> subpopulation transition in the absence of IL-17 receptor A

Previous reports have suggested that Gr1<sub>high</sub> to Gr1<sub>low</sub> monocyte conversion occurs in the periphery [10,11]. To investigate Gr1<sub>high</sub> to Gr1<sub>low</sub> monocyte conversion in the absence of IL-17 receptor A, we used fluorescent bead labeling [13] in mixed chimeric mice. Initial labeling of both subsets and bead clearance from Gr1<sub>high</sub> cells was similar for both genotypes (figure 7A,B). Consistent with conversion of Gr1<sub>high</sub> to Gr1<sub>low</sub> monocytes and as described, a delayed rise in the proportion of bead<sup>+</sup>Gr1<sub>low</sub> cells occurred in wt cells (figure 7B) [13]. However,
this was completely absent in Gr1<sup>low</sup>Il17ra<sup>-/-</sup> monocytes in an identical environment.

To assess monocyte subtype conversion with an independent stable cell labeling method, proliferating cells in resting mixed chimeric mice were pulse labeled with BrdU and peripheral monocyte BrdU content assessed over time (figure 7C). The proportion of BrdU<sup>+</sup> among Gr1<sup>high</sup> monocytes of both genotypes rose simultaneously during the first day and decreased afterwards. This is consistent with the similar proliferation of bone marrow monocytes (figure 7D) and suggests no difference in liberation from the bone marrow. Among Gr1<sup>low</sup> monocytes of wt genotype, the rise in the BrdU<sup>+</sup> proportion was sustained until day 6, likely due to repopulation by peripheral conversion of Gr1<sup>high</sup> cells. In contrast, among the low absolute numbers of Gr1<sup>low</sup>Il17ra<sup>-/-</sup> monocytes, only an initial rise in the BrdU<sup>+</sup> proportion on day one was observed, similar to Gr1<sup>high</sup> cells of either genotype. No delayed rise as in the Gr1<sup>low</sup> wt monocyte population occurred, the proportion of pulse-labeled Gr1<sup>low</sup>Il17ra<sup>-/-</sup> monocytes rather steadily declined. Also in the bone marrow, among the reduced number of Gr1<sup>low</sup>Il17ra<sup>-/-</sup> monocytes (figure 5D), the proportion of Gr1<sup>high</sup> cells was significantly higher than of wtGr1<sup>low</sup> monocytes and similar to what was observed in Gr1<sup>high</sup> monocytes of either genotype (figure 7C). This can account for the higher initial proportion of blood BrdU<sup>+</sup> among Gr1<sup>low</sup>Il17ra<sup>-/-</sup> than wt monocytes and indicates a larger proportion of recent cell divisions in this group.

These data suggest that Gr1<sup>high</sup> to Gr1<sup>low</sup> monocyte conversion is altered in the absence of Il17ra<sup>-/-</sup>.

Figure 6. Lack maintenance of Il17ra<sup>-/-</sup>Gr1<sup>low</sup> monocyte population after normal initial recovery. (A-D) Mixed bone marrow chimeric wt/Il17ra<sup>-/-</sup> mice underwent monocyte depletion by liposomal clodronate. During recovery, monocyte genotype (A), proportion of Gr1<sup>high</sup> and Gr1<sup>low</sup> cells among the monocytes of each genotype (B) and absolute blood concentrations of Gr1<sup>high</sup> (C) and Gr1<sup>low</sup> monocytes (D) of each genotype were measured (n = 8, 2 independent transplantations, Bonferroni after two-way-ANOVA).

doi:10.1371/journal.pone.0085461.g006

IL-17ra<sup>-/-</sup> macrophage generation in peritonitis

Monocyte subtypes are differentially recruited to sites of inflammation. We studied peritonitis as a model of preferential Gr1<sup>high</sup> monocyte accumulation and acute inflammatory macrophage accumulation. Consistently, after 10 h of inflammation, neither the proportion of Il17ra<sup>-/-</sup> PMN nor of Il17ra<sup>-/-</sup> monocytes in the peritoneal cavity was lower than in peripheral blood at the start of the experiment (figure 8A,B). Il17ra<sup>-/-</sup> monocytes were even overrepresented in the peritoneal infiltrate (figure 8B). After three days of inflammation, the proportion of wt and Il17ra<sup>-/-</sup>CD11b<sup>+</sup> macrophages in the peritoneum was not different from peripheral blood before induction of inflammation, while blood Il17ra<sup>-/-</sup> monocytes were depleted (figure 8C). While Gr1<sup>high</sup> and Gr1<sup>low</sup> monocytes were no longer distinguishable in peritoneal inflammation, we further analyzed CD11c that is expressed on Gr1<sup>low</sup> monocytes and on some macrophage subtypes such as pulmonary and vascular macrophages [1–3,29]. Compared to wt cells from the same mouse, CD11c expression was significantly lower on Il17ra<sup>-/-</sup> cells (figure 8D), similarly to what was previously observed in complete Il17ra<sup>-/-</sup> mice [21].

Role of myeloid IL-17ra<sup>-/-</sup> in renal macrophage accumulation and fibrosis

To test whether the decrease in Gr1<sup>low</sup> monocytes was functionally relevant, we investigated kidney injury induced by unilateral ureteral obstruction (UUO) that induces macrophage accumulation and renal fibrosis [30,31]. To assess the IL-17 effect on individual myeloid cells, renal infiltration was investigated.
in mixed chimeric wt/Il17ra⁻/⁻ mice seven days after obstruction surgery (figure 9). UUO significantly enhanced renal CD11b⁺ leukocyte accumulation (figure 9A). Similar to other organs (figure 4), the proportion of CD11b⁺Il17ra⁻/⁻ cells was already lower than wt in the unobstructed contralateral kidney. This was significantly enhanced in obstructive inflammation (figure 9B). Differential recruitment was mainly due to monocytes and not neutrophils, which were 39±6% Il17ra⁻/⁻ (p = 0.13, n = 6, 2

Figure 7. Kinetics of labeled Gr¹high and Gr¹low monocytes in the presence and absence of Il17ra⁻/⁻. (A,B) Monocytes in mixed chimeric wt/Il17ra⁻/⁻ mice were labeled with fluorescent latex beads (A). The proportion of labeled CD11b⁺CD115⁺ cells among each monocyte subgroup (Gr¹high and Gr¹low monocytes) within each genotype was assessed over time (B, n = 4-5, 2 independent transplantations, Bonferroni after ANOVA). (C) Dividing cells in mixed bone marrow chimeric wt/Il17ra⁻/⁻ mice labeled with a single BrdU injection and peripheral blood monocytes were analyzed for BrdU incorporation at the indicated timepoints. In every animal, the proportion of labeled cells among Gr¹high and Gr¹low monocytes of either genotype was assessed over time (n = 4, * indicates sign. differences between wt and Il17ra⁻/⁻ Gr¹low monocytes at the indicated timepoints, # indicates a sign. change over time within wt (black bars) or Il17ra⁻/⁻ (white bars) Gr¹low monocytes, analysis with Bonferroni after ANOVA). (D) Proliferation of bone marrow Gr¹high and Gr¹low monocytes of both genotypes was assessed 20 h after BrdU injection (n = 7 from 2 independent transplantations, Bonferroni after ANOVA). doi:10.1371/journal.pone.0085461.g007

Figure 8. In peritonitis, Il17ra⁻/⁻ monocyte recruitment is sustained, but macrophage phenotype changed. (A,B) Peritonitis was induced in mixed bone marrow chimeric wt/Il17ra⁻/⁻ mice. Peripheral blood (at start and end of the experiment) and peritoneal neutrophils (PMN, CD11b⁺CD115⁻ Gr¹high, A) and monocytes (CD11b⁺CD115⁺, B) were analyzed by flow cytometry after 10 h (n = 4, Bonferroni after ANOVA). (C) At day 3, intraperitoneal myeloid CD11b⁺ cells were analyzed and compared to peripheral blood monocytes at start and end of the experiment (n = 4-6, 2 independent transplantations, Bonferroni after ANOVA). (D) CD11c expression on wt and Il17ra⁻/⁻ myeloid (CD11b⁺) cells was compared in lung, spleen, resting and inflamed peritoneal cavity of mixed bone marrow chimeric wt/Il17ra⁻/⁻ mice (n = 4–8, paired t-tests). doi:10.1371/journal.pone.0085461.g008
Independent transplantations). Obstruction also increased CD11c and F4/80 expression on myeloid cells at day 7 (figure 9C). This phenotype was significantly less pronounced in the cells deficient in IL-17 signaling. A pro-fibrotic profile has been described for Gr1<sup>high</sup>-derived Gr1<sup>low</sup> monocytes/macrophages in renal fibrosis [32]. Among Il17ra<sup>−/−</sup> cells, the proportion of these Gr1<sup>low</sup> cells was significantly lower than in wt cells in the same environment (figure 9D). UUO markedly increased proliferation of renal leukocytes (figure 9E). This was significantly dampened in the absence of Il17ra.

Renal histology was assessed in mice reconstituted with either wt or Il17ra<sup>−/−</sup> bone marrow (figure 10). The proportion of fibrotic tissue area assessed with Sirius red staining and anti-aSMA staining was significantly lower in the absence of bone marrow Il17ra (figure 10A-C). mRNA expression of the pro-fibrotic molecules collagen I, fibronectin and CTGF was also significantly decreased (figure 10D). Leukocyte infiltration is difficult to compare in kidney at different stages of fibrosis, however, there was a tendency towards less absolute CD45<sup>+</sup> and CD11b<sup>+</sup> leukocyte infiltration in the absence of myeloid Il17ra in complete bone marrow chimeric mice (data not shown). These data suggest that lack of IL-17 receptor A on the myeloid cell level significantly alters inflammation and diminishes fibrosis in renal obstruction.

Discussion

Our data demonstrate a role for IL-17 receptor in maintenance of the Gr1<sup>low</sup> monocyte population and macrophages in vivo.

Most markedly in mixed chimeric mice, where cell-specific effects can be tested, Il17ra<sup>−/−</sup>Gr1<sup>low</sup> monocyte numbers were decreased. Different from the monocyte phenotype observed in M-CSF receptor CD115 blockade or M-CSF scavenging [7,8] or deficiency in nuclear receptor NUR77 [9] we did not observe significant differences in monocyte cell death between the genotypes. Also, bone marrow progenitors and initial recovery after monocyte depletion was unaltered.

Our data might suggest a different mechanism how IL-17 modulates monocyte counts; Gr1<sup>high</sup> to Gr1<sup>low</sup> monocyte passage was altered and appeared defective in Il17ra<sup>−/−</sup> monocytes. While a
specific genetic marker that could indicate the passage from Gr1\textsuperscript{high} to Gr1\textsuperscript{low} is not currently available, we made efforts to study this phenomenon as directly as possible with two independent methods, BrdU pulse-labeling and injection of latex beads [13] with very similar results. Consistent with this interpretation of the data, bone marrow Il17ra\textsuperscript{-/-} Gr1\textsuperscript{low} monocytes had more recently proliferated than wtGr1\textsuperscript{low} cells which would be expected in the absence of or at strongly reduced rates of cells converted from Gr1\textsuperscript{high} cells. Interestingly, initial Il17ra\textsuperscript{-/-} Gr1\textsuperscript{low} monocyte recovery after monocyte depletion was normal. This is consistent with the hypothesis that some Gr1\textsuperscript{low} monocytes may be different from the large proportion of Gr1\textsuperscript{low} monocytes that is observed in wt cells under resting conditions regarding their requirement of the Il17ra signal. Genetic labeling techniques will be required to further test this proposition.

Gr1\textsuperscript{low} monocytes are precursors of pulmonary resident macrophages [12,15]. Indeed, we found that the proportion of Il17ra\textsuperscript{-/-} cells was decreased among resident pulmonary and also

---

**Figure 10. Decreased renal fibrosis in the absence of IL-17 receptor on myeloid cells.** Unilateral ureteral obstruction was performed in wt and Il17ra\textsuperscript{-/-} bone marrow chimeric mice. (A–C) Histologic assessment of fibrosis was conducted after Masson’s trichrome (A), Sirius red (B), birefringent sirius red positive fibrotic tissue area analyzed from n = 5/group from 2 independent transplantations, 40 x original magnification) and αSMA-immunofluorescent staining (C, n = 7 from 2 independent transplantations, scale bar = 100 μm) on day 7. (D) mRNA expression of collagen I, fibrinonectin and CTGF was assessed in obstructed kidneys by quantitative PCR (day seven, n = 3, t-tests).

doi:10.1371/journal.pone.0085461.g010
and/or specific inflammatory conditions. They are required or they can substitute for another at baseline binding cytokines is required to elucidate whether all of Il17ra found a decrease in nephritis, [35] and diabetic nephropathy [36]. In addition to anti-M-CSF receptor therapy that inhibits macrophage accumulation of dendritic cells in mice, is consistent with a direct IL-17 effect. Il17ra that enhances antigen presenting cell function [33]. Our data showing that IL-17 mediates immunity against this pathogen and IL-17 fibrosis is associated with macrophage accumulation. We investigated the effect of Il17ra on myeloid cells in renal fibrosis and found a decrease in Il17ra+ macrophages in direct comparison of wt and Il17ra- cells in mixed chimeric mice. This is reminiscent of anti-M-CSF receptor therapy that inhibits macrophage accumulation in renal inflammation in ureteral obstruction [34], lupus nephritis, [35] and diabetic nephropathy [36]. In addition to reduced numbers, their phenotype was altered. In UUO, Gr1high-derived Gr1low monocytes/macrophages have been shown to express pro-fibrotic mediators [32]. Our results show that this group was significantly decreased in the absence of Il17ra. Our study prompts further investigation of functional differences between wt and Il17ra-+ macrophages and macrophages. This will also help to take into account possible compensatory mechanisms in the complete absence of Il17ra. Blood monocyte TNFα production in response to LPS was very similar in wt and Il17ra-+ in the same environment (data not shown) and phagocytosis of latex beads was very similar (figure 7), however, this may be altered for different substrates and during macrophage differentiation.

Recent reports propose IL-17A as an important mediator in non-renal fibrosis, bleomycin induced pulmonary fibrosis [37,38] and hepatic fibrosis induced by either cholestasis or hepatotoxic agents [39]. Interestingly, the decrease in hepatic fibrosis was completely mediated by Il17ra deficiency on hematopoietic cells [39]. Also in the kidney, our experiments show a highly significant decrease in fibrosis in mice deficient only in bone-marrow Il17ra. Our finding that Il17a modulates myeloid cell infiltration and phenotype in renal fibrosis may therefore represent a mechanism also for the hepatic disease. As IL-17 receptor ligands are soluble serum factors, blockade should be investigated as a therapeutic targets in the treatment of pro-inflammatory disease processes in tissue fibrosis.

In summary, our data demonstrate Il17a a novel regulator of monocyte homeostasis and macrophage development during fibrosis in vivo.

Acknowledgments

The authors would like to thank H. Richi for expert technical assistance.

Author Contributions

Conceived and designed the experiments: SG SVV. Performed the experiments: SG BH NS SR. Analyzed the data: SG AMD RS SVV. Contributed reagents/materials/analysis tools: AMD. Wrote the paper: SG HH SVV.

References

1. Geissmann F, Manz MG, Jung S, Sieweke MH, Merad M, et al. (2010) Development of monocytes, macrophages, and dendritic cells. Science 327: 656–661.
2. Ingersoll MA, Platt AM, Potteaux S, Randolph GF (2011) Monocyte trafficking in acute and chronic inflammation. Trends Immunol 32: 470–477.
3. Shi C, Pamer EG (2011) Monocyte-mediated defense against microbial pathogens. Annu Rev Immunol 26: 421–452.
4. Geissmann F, Jung S, Littman DR (2003) Blood monocytes consist of two principal subsets with distinct migratory properties. Immunity 19: 71–82.
5. Ingersoll MA, Spanbroek K, Lottaz C, Ganier EL, Frankenberg M, et al. (2010) Comparison of gene expression profiles between human and mouse monocyte subsets. Blood 115: e10–19.
6. Hashimoto D, Chow A, Greter M, Saenger Y, Kwan WH, et al. (2011) Pretransplant CSF-1 therapy expands recipient macrophages and ameliorates GVHD after allogeneic hematopoietic cell transplantation. J Exp Med 208: 1069–1082.
7. MacDonald KP, Palmer JS, Cronau S, Seppanen E, Olver S, et al. (2010) An antibody against the colony-stimulating factor 1 receptor depletes the resident subset of monocytes and tissue- and tumor-associated macrophages but does not inhibit inflammation. Blood 116: 3955–3963.
8. Hanno RN, Carlin LM, Hubbeling HG, Nakiciewicz D, Green AM, et al. (2011) The transcription factor NR4A1 (Nur77) controls bone marrow differentiation and the survival of Ly6C+ monocytes. Nat Immunol 12: 778–785.
9. Sundekutter G, Nikola T, Dillon MJ, Van Rooijen N, Stilling M, et al. (2004) Subpopulations of mouse blood monocytes differ in maturation stage and inflammatory response. J Immunol 172: 4410–4417.
10. Swirski FK, Libby P, Akouna E, Alcaide P, Lukincuskis FW, et al. (2007) Ly-6Chi monocytes dominate hypercholesterolemia-associated monocytopoeisis and give rise to macrophages in atheroma. J Clin Invest 117: 195–205.
11. Yona S, Kim KW, Wolf Y, Mildner A, Varol D, et al. (2013) Fate Mapping Reveals Origins and Dynamics of Monocytes and Tissue Macrophages under Homeostasis. Immunity 38: 79–91.
12. Tacke F, Ghinhoux F, Jakubzick C, van Rooijen N, Merad M, et al. (2006) Immature monocytes acquire antigens from other cells in the bone marrow and present them to T cells after maturing in the periphery. J Exp Med 203: 503–597.
13. Tacke F, Ghinhoux F, Jakubzick C, van Rooijen N, Merad M, et al. (2006) Immature monocytes acquire antigens from other cells in the bone marrow and present them to T cells after maturing in the periphery. J Exp Med 203: 503–597.
14. Peng Y, Latchman Y, Elkon KB (2009) Ly6C(low) monocytes differentiate into dendritic cells and cross-tolerize T cells through PDL-1. J Immunol 182: 2777–2785.
15. Jakubzick C, Tacke F, Ghinhoux F, Wagener AJ, van Rooijen N, et al. (2008) Blood monocyte subsets differentially give rise to CD103+ and CD103-pulmonary dendritic cell populations. J Immunol 180: 3019–3027.
16. Tacke F, Alvarez D, Kaplan TJ, Jakubzick C, Spanbroek R, et al. (2007) Monocyte subsets differentially employ CCR2, CCR5, and CX3CR1 to accumulate within atherosclerotic plaques. J Clin Invest 117: 183–194.
17. Auffray C, Fogg D, Garfa M, Elain G, Join-Lambert O, et al. (2007) Monitoring implications for airway inflammation in cystic fibrosis. J Immunol 175: 404–412.
18. Iwakura Y, Ishigame H, Saji S, Nakae S (2011) Functional specialization of interleukin-17 family members. Immunity 34: 149–162.
20. Onishi RM, Gaffen SL (2010) Interleukin-17 and its target genes: mechanisms of interleukin-17 function in disease. Immunology 129: 311–321.

21. von Vietinghoff S, Kolsova EK, Mestas J, Diehl CJ, Witztum JL, et al. (2011) Mycophenolate mofetil decreases atherosclerotic lesion size by depression of aortic T-lymphocyte and interleukin-17-mediated macrophage accumulation. J Am Coll Cardiol 57: 2194–2204.

22. von Vietinghoff S, Ouyang H, Ley K (2010) Mycophenolic acid suppresses granulopoiesis by inhibition of interleukin-17 production. Kidney Int 78: 79–80.

23. Barm JC, Christian Baldeviano G, Talor MV, Wu L, Ong S, et al. (2011) Macrophages participate in IL-17-mediated inflammation. Eur J Immunol.

24. Van Rooijen N, Sanders A (1994) Liposome mediated depletion of macrophages: mechanism of action, preparation of liposomes and applications. J Immunol Methods 174: 83–93.

25. Sorensen I, Stunk N, Inheter T, Degen JL, Melk A, et al. (2011) Fibrinogen, acting as a mitogen for tubulointerstitial fibroblasts, promotes renal fibrosis. Kidney Int 80: 1035–1044.

26. Rickel EA, Siegel LA, Yoon BR, Rotman JB, Kugler DG, et al. (2008) Identification of functional roles for both IL-17RB and IL-17RA in mediating IL-25-induced activities. J Immunol 181: 4299–4310.

27. Song X, Zhu S, Shi P, Liu Y, Shi Y, et al. (2011) IL-17RE is the functional receptor for IL-17C and mediates mucosal immunity to infection with intestinal pathogens. Nat Immunol 12: 1151–1158.

28. Lim AK, Ma FY, Nikolic-Paterson DJ, Thomas MC, Hurst LA, et al. (2009) Antibody blockade of c-fms suppresses the progression of inflammation and injury in early diabetic nephropathy in obese db/db mice. Diabetologia 52: 1669–1679.

29. Wilson MS, Madala SK, Ramalingam TR, Gochuico BR, Rosas IO, et al. (2010) Bleomycin and IL-1beta-mediated pulmonary fibrosis is IL-17A dependent. J Exp Med 207: 353–352.

30. Meng F, Wang K, Aoyama T, Grivennikov SI, Paik Y, et al. (2012) Interleukin-17 signaling in inflammatory, kupffer cells, and hepatic stellate cells exacerbates liver fibrosis in mice. Gastroenterology 143: 765–776 e763.